| __timestamp | Amphastar Pharmaceuticals, Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 1513000 |
| Thursday, January 1, 2015 | 37065000 | 12573000 |
| Friday, January 1, 2016 | 41199000 | 42238000 |
| Sunday, January 1, 2017 | 43415000 | 69800000 |
| Monday, January 1, 2018 | 57564000 | 113773000 |
| Tuesday, January 1, 2019 | 68853000 | 179362000 |
| Wednesday, January 1, 2020 | 67229000 | 266946000 |
| Friday, January 1, 2021 | 60932000 | 438633000 |
| Saturday, January 1, 2022 | 74771000 | 461645000 |
| Sunday, January 1, 2023 | 73741000 | 387332000 |
| Monday, January 1, 2024 | 320653000 |
Cracking the code
In the rapidly evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, CRISPR Therapeutics AG has consistently outpaced Amphastar Pharmaceuticals, with R&D expenses growing by an impressive 25,500% from 2014 to 2022. In contrast, Amphastar's R&D spending increased by approximately 160% over the same period.
CRISPR Therapeutics AG's peak spending in 2022 was nearly six times that of Amphastar, highlighting its aggressive pursuit of cutting-edge genetic research. Meanwhile, Amphastar's steady growth reflects a more conservative strategy, focusing on incremental advancements. This divergence underscores the varied paths companies take in the biotech sector, balancing risk and innovation to drive future breakthroughs.
Novartis AG vs Amphastar Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Biogen Inc. and CRISPR Therapeutics AG Allocate Funds
Comparing Innovation Spending: Biogen Inc. and Amphastar Pharmaceuticals, Inc.
R&D Insights: How Summit Therapeutics Inc. and Amphastar Pharmaceuticals, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
R&D Insights: How Ionis Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for TG Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Ligand Pharmaceuticals Incorporated
Research and Development: Comparing Key Metrics for PTC Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Research and Development Investment: Mesoblast Limited vs Amphastar Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Amphastar Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Research and Development Investment: Amphastar Pharmaceuticals, Inc. vs Xencor, Inc.